Tag: Zydus Lifesciences
CSIR-CDRI Lucknow and Zydus to develop best-in-class drug for CKD induced...
Under this agreement, CDRI and Zydus will jointly undertake preclinical research. Any drug candidate emerging from the efforts will be developed by Zydus for India and other markets
Zydus Lifesciences completes Phase II(a) clinical trial of Usnoflast in ALS...
Usnoflast, a novel oral NLRP3 inflammasome inhibitor, shows promising results in reducing neurodegeneration and improving key health markers
Zydus to acquire 50% stake in Sterling Biotech to enter into...
Post this transaction, Sterling Biotech will become a 50:50 Joint Venture with equal representation on the Board
Zydus Lifesciences secures COFEPRIS approval to market MamitraTM in Mexico for...
With the approval of MamitraTM, Zydus aims to provide affordable cancer treatments for HER2-positive breast and gastric cancer patients
Zydus and Takeda partner to market Vonoprazan in India
Innovative drug to offer new treatment options for GERD and acid peptic disorders, enhancing healthcare in India
Zydus Lifesciences records revenue growth of Rs 195,474 million in FY24
Zydus Lifesciences reports stellar financial performance for Q4 & FY24 with significant increases in revenue, EBITDA, and net profit; the board recommends a 300% dividend
Zydus completes EPICS-IIITM trial enrollment for Saroglitazar Mg in PBC treatment
Zydus Lifesciences achieves a milestone in its research by successfully enrolling participants for the EPICS-IIITM Phase 2b/3 trial, evaluating Saroglitazar Mg's efficacy in treating Primary Biliary Cholangitis (PBC), a rare autoimmune liver disease
Zydus Lifesciences acquires 6.5% stake in Mylab via its subsidiary ZAHIL
The acquisition represents collective vision to transform healthcare by combining therapeutic expertise in human formulations and diagnostic capabilities of the two companies
Zydus’s two-dose Covid-19 vaccine, ZyCoV-D receives EUA from DCGI
The two-dose regimen has been approved in the age group of 12 years and above
Zydus subsidiary supported drug data for Menkes disease set to be...
Fortress Biotech and Cyprium Therapeutics alongwith Zydus Lifesciences’ Sentynl Therapeutics announce CUTX-101, copper histidinate data to be presented at 2022 American College of Medical Genetics Annual Clinical Genetics Meeting